Global Intranasal Corticosteroids Market
Global Intranasal Corticosteroids Market

Intranasal Corticosteroids Comprehensive Study by Type (Prescribed Drugs, OTC Drugs), Application (Hospital Pharmacies, Online Pharnacies, Retail Pharmacies), Indication (Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis (SAR), Nonallergic Rhinitis), Dosage (Spray, Aerosol Liquid, Implant), End User (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Online Pharmacies), System (Multi-dose Systems, Bi-dose Systems, Unit-dose Systems) Players and Region - Global Market Outlook to 2025

Intranasal Corticosteroids Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Aug 2020 Edition 201 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Intranasal Corticosteroids Market Overview:
Intranasal corticosteroids belong to the family of the medicines called steroids. These steroids can be sprayed or inhaled into the nose to help relieve the stuffy nose, the discomfort of fever, irritation of other allergies, and the nasal problems. It offers small therapeutic benefits in acute sinusitis as well. According to NCBI standard, Acute sinusitis is a common condition, affecting an estimated 31 million Americans annually . Some of the players profiled in the study are GlaxoSmithKline (United Kingdom), Merck (United States), Sanofi (France), Sumitomo Corporation (Japan), Teva Pharmaceuticals (Israel), Johnson and Johnson (United States), AstraZeneca(United Kingdom), Merck & Co., Inc. (United States), Novartis AG (Switzerland) and Pfizer, Inc. (United States.

On the basis of geography, the market of Intranasal Corticosteroids has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Indication, the sub-segment i.e. Perennial Allergic Rhinitis (PAR) will boost the Intranasal Corticosteroids market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage, the sub-segment i.e. Spray will boost the Intranasal Corticosteroids market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital Pharmacies will boost the Intranasal Corticosteroids market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by System, the sub-segment i.e. Multi-dose Systems will boost the Intranasal Corticosteroids market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Adoption of Self-Administration Practices
  • The Increasing Awareness about Use of Intranasal Corticosteroids


Restraints
  • Adverse Effects of Drug Failures

Opportunities
  • Increasing Demand For Self Administrative Drug Delivery
  • Expanding Therapeutic Applications For Intranasal Corticosteroids Sprays

Challenges
  • Compliance Of Inhaling Intranasal Corticosteroids Sprays


In December 2019 Sanofi acquired synthrox for its immuno-oncology pipeline. This merger helps to build a portfolio of high-quality assets and to lead with innovations. This acquisition is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement.


Target Audience:
New Entrants/Investors, Analysts and Strategic Business Planners, Intranasal Corticosteroids Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Intranasal Corticosteroids market on the basis of product [Prescribed Drugs and OTC Drugs] , application [Hospital Pharmacies, Online Pharnacies and Retail Pharmacies], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Intranasal Corticosteroids market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Intranasal Corticosteroids industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Pfizer, Inc. (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Intranasal Corticosteroids market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Prescribed Drugs
  • OTC Drugs
By Application
  • Hospital Pharmacies
  • Online Pharnacies
  • Retail Pharmacies
By Indication
  • Perennial Allergic Rhinitis (PAR)
  • Seasonal Allergic Rhinitis (SAR)
  • Nonallergic Rhinitis

By Dosage
  • Spray
  • Aerosol Liquid
  • Implant

By End User
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

By System
  • Multi-dose Systems
  • Bi-dose Systems
  • Unit-dose Systems

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Adoption of Self-Administration Practices
      • 3.2.2. The Increasing Awareness about Use of Intranasal Corticosteroids
    • 3.3. Market Challenges
      • 3.3.1. Compliance Of Inhaling Intranasal Corticosteroids Sprays
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Intranasal Corticosteroids, by Type, Application, Indication, Dosage, End User, System and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Intranasal Corticosteroids (Value)
      • 5.2.1. Global Intranasal Corticosteroids by: Type (Value)
        • 5.2.1.1. Prescribed Drugs
        • 5.2.1.2. OTC Drugs
      • 5.2.2. Global Intranasal Corticosteroids by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Online Pharnacies
        • 5.2.2.3. Retail Pharmacies
      • 5.2.3. Global Intranasal Corticosteroids by: Indication (Value)
        • 5.2.3.1. Perennial Allergic Rhinitis (PAR)
        • 5.2.3.2. Seasonal Allergic Rhinitis (SAR)
        • 5.2.3.3. Nonallergic Rhinitis
      • 5.2.4. Global Intranasal Corticosteroids by: Dosage (Value)
        • 5.2.4.1. Spray
        • 5.2.4.2. Aerosol Liquid
        • 5.2.4.3. Implant
      • 5.2.5. Global Intranasal Corticosteroids by: End User (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Drug Stores
        • 5.2.5.3. Retail Pharmacies
        • 5.2.5.4. Online Pharmacies
      • 5.2.6. Global Intranasal Corticosteroids by: System (Value)
        • 5.2.6.1. Multi-dose Systems
        • 5.2.6.2. Bi-dose Systems
        • 5.2.6.3. Unit-dose Systems
      • 5.2.7. Global Intranasal Corticosteroids Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Intranasal Corticosteroids (Volume)
      • 5.3.1. Global Intranasal Corticosteroids by: Type (Volume)
        • 5.3.1.1. Prescribed Drugs
        • 5.3.1.2. OTC Drugs
      • 5.3.2. Global Intranasal Corticosteroids by: Application (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Online Pharnacies
        • 5.3.2.3. Retail Pharmacies
      • 5.3.3. Global Intranasal Corticosteroids by: Indication (Volume)
        • 5.3.3.1. Perennial Allergic Rhinitis (PAR)
        • 5.3.3.2. Seasonal Allergic Rhinitis (SAR)
        • 5.3.3.3. Nonallergic Rhinitis
      • 5.3.4. Global Intranasal Corticosteroids by: Dosage (Volume)
        • 5.3.4.1. Spray
        • 5.3.4.2. Aerosol Liquid
        • 5.3.4.3. Implant
      • 5.3.5. Global Intranasal Corticosteroids by: End User (Volume)
        • 5.3.5.1. Hospital Pharmacies
        • 5.3.5.2. Drug Stores
        • 5.3.5.3. Retail Pharmacies
        • 5.3.5.4. Online Pharmacies
      • 5.3.6. Global Intranasal Corticosteroids by: System (Volume)
        • 5.3.6.1. Multi-dose Systems
        • 5.3.6.2. Bi-dose Systems
        • 5.3.6.3. Unit-dose Systems
      • 5.3.7. Global Intranasal Corticosteroids Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
  • 6. Intranasal Corticosteroids: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sumitomo Corporation (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson and Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca(United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer, Inc. (United States
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Intranasal Corticosteroids Sale, by Type, Application, Indication, Dosage, End User, System and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Intranasal Corticosteroids (Value)
      • 7.2.1. Global Intranasal Corticosteroids by: Type (Value)
        • 7.2.1.1. Prescribed Drugs
        • 7.2.1.2. OTC Drugs
      • 7.2.2. Global Intranasal Corticosteroids by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Online Pharnacies
        • 7.2.2.3. Retail Pharmacies
      • 7.2.3. Global Intranasal Corticosteroids by: Indication (Value)
        • 7.2.3.1. Perennial Allergic Rhinitis (PAR)
        • 7.2.3.2. Seasonal Allergic Rhinitis (SAR)
        • 7.2.3.3. Nonallergic Rhinitis
      • 7.2.4. Global Intranasal Corticosteroids by: Dosage (Value)
        • 7.2.4.1. Spray
        • 7.2.4.2. Aerosol Liquid
        • 7.2.4.3. Implant
      • 7.2.5. Global Intranasal Corticosteroids by: End User (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Drug Stores
        • 7.2.5.3. Retail Pharmacies
        • 7.2.5.4. Online Pharmacies
      • 7.2.6. Global Intranasal Corticosteroids by: System (Value)
        • 7.2.6.1. Multi-dose Systems
        • 7.2.6.2. Bi-dose Systems
        • 7.2.6.3. Unit-dose Systems
      • 7.2.7. Global Intranasal Corticosteroids Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Intranasal Corticosteroids (Volume)
      • 7.3.1. Global Intranasal Corticosteroids by: Type (Volume)
        • 7.3.1.1. Prescribed Drugs
        • 7.3.1.2. OTC Drugs
      • 7.3.2. Global Intranasal Corticosteroids by: Application (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Online Pharnacies
        • 7.3.2.3. Retail Pharmacies
      • 7.3.3. Global Intranasal Corticosteroids by: Indication (Volume)
        • 7.3.3.1. Perennial Allergic Rhinitis (PAR)
        • 7.3.3.2. Seasonal Allergic Rhinitis (SAR)
        • 7.3.3.3. Nonallergic Rhinitis
      • 7.3.4. Global Intranasal Corticosteroids by: Dosage (Volume)
        • 7.3.4.1. Spray
        • 7.3.4.2. Aerosol Liquid
        • 7.3.4.3. Implant
      • 7.3.5. Global Intranasal Corticosteroids by: End User (Volume)
        • 7.3.5.1. Hospital Pharmacies
        • 7.3.5.2. Drug Stores
        • 7.3.5.3. Retail Pharmacies
        • 7.3.5.4. Online Pharmacies
      • 7.3.6. Global Intranasal Corticosteroids by: System (Volume)
        • 7.3.6.1. Multi-dose Systems
        • 7.3.6.2. Bi-dose Systems
        • 7.3.6.3. Unit-dose Systems
      • 7.3.7. Global Intranasal Corticosteroids Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Intranasal Corticosteroids: by Type(USD Million)
  • Table 2. Intranasal Corticosteroids Prescribed Drugs , by Region USD Million (2014-2019)
  • Table 3. Intranasal Corticosteroids OTC Drugs , by Region USD Million (2014-2019)
  • Table 4. Intranasal Corticosteroids: by Application(USD Million)
  • Table 5. Intranasal Corticosteroids Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 6. Intranasal Corticosteroids Online Pharnacies , by Region USD Million (2014-2019)
  • Table 7. Intranasal Corticosteroids Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 8. Intranasal Corticosteroids: by Indication(USD Million)
  • Table 9. Intranasal Corticosteroids Perennial Allergic Rhinitis (PAR) , by Region USD Million (2014-2019)
  • Table 10. Intranasal Corticosteroids Seasonal Allergic Rhinitis (SAR) , by Region USD Million (2014-2019)
  • Table 11. Intranasal Corticosteroids Nonallergic Rhinitis , by Region USD Million (2014-2019)
  • Table 12. Intranasal Corticosteroids: by Dosage(USD Million)
  • Table 13. Intranasal Corticosteroids Spray , by Region USD Million (2014-2019)
  • Table 14. Intranasal Corticosteroids Aerosol Liquid , by Region USD Million (2014-2019)
  • Table 15. Intranasal Corticosteroids Implant , by Region USD Million (2014-2019)
  • Table 16. Intranasal Corticosteroids: by End User(USD Million)
  • Table 17. Intranasal Corticosteroids Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 18. Intranasal Corticosteroids Drug Stores , by Region USD Million (2014-2019)
  • Table 19. Intranasal Corticosteroids Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 20. Intranasal Corticosteroids Online Pharmacies , by Region USD Million (2014-2019)
  • Table 21. Intranasal Corticosteroids: by System(USD Million)
  • Table 22. Intranasal Corticosteroids Multi-dose Systems , by Region USD Million (2014-2019)
  • Table 23. Intranasal Corticosteroids Bi-dose Systems , by Region USD Million (2014-2019)
  • Table 24. Intranasal Corticosteroids Unit-dose Systems , by Region USD Million (2014-2019)
  • Table 25. South America Intranasal Corticosteroids, by Country USD Million (2014-2019)
  • Table 26. South America Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 27. South America Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 28. South America Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 29. South America Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 30. South America Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 31. South America Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 32. Brazil Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 33. Brazil Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 34. Brazil Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 35. Brazil Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 36. Brazil Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 37. Brazil Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 38. Argentina Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 39. Argentina Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 40. Argentina Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 41. Argentina Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 42. Argentina Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 43. Argentina Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 44. Rest of South America Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 45. Rest of South America Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 46. Rest of South America Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 47. Rest of South America Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 48. Rest of South America Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 49. Rest of South America Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 50. Asia Pacific Intranasal Corticosteroids, by Country USD Million (2014-2019)
  • Table 51. Asia Pacific Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 52. Asia Pacific Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 53. Asia Pacific Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 54. Asia Pacific Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 55. Asia Pacific Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 56. Asia Pacific Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 57. China Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 58. China Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 59. China Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 60. China Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 61. China Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 62. China Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 63. Japan Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 64. Japan Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 65. Japan Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 66. Japan Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 67. Japan Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 68. Japan Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 69. India Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 70. India Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 71. India Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 72. India Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 73. India Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 74. India Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 75. South Korea Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 76. South Korea Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 77. South Korea Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 78. South Korea Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 79. South Korea Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 80. South Korea Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 81. Taiwan Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 82. Taiwan Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 83. Taiwan Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 84. Taiwan Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 85. Taiwan Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 86. Taiwan Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 87. Australia Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 88. Australia Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 89. Australia Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 90. Australia Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 91. Australia Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 92. Australia Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 93. Rest of Asia-Pacific Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 94. Rest of Asia-Pacific Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 95. Rest of Asia-Pacific Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 96. Rest of Asia-Pacific Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 97. Rest of Asia-Pacific Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 98. Rest of Asia-Pacific Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 99. Europe Intranasal Corticosteroids, by Country USD Million (2014-2019)
  • Table 100. Europe Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 101. Europe Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 102. Europe Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 103. Europe Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 104. Europe Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 105. Europe Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 106. Germany Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 107. Germany Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 108. Germany Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 109. Germany Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 110. Germany Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 111. Germany Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 112. France Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 113. France Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 114. France Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 115. France Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 116. France Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 117. France Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 118. Italy Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 119. Italy Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 120. Italy Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 121. Italy Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 122. Italy Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 123. Italy Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 124. United Kingdom Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 125. United Kingdom Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 126. United Kingdom Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 127. United Kingdom Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 128. United Kingdom Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 129. United Kingdom Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 130. Netherlands Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 131. Netherlands Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 132. Netherlands Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 133. Netherlands Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 134. Netherlands Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 135. Netherlands Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 136. Rest of Europe Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 137. Rest of Europe Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 138. Rest of Europe Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 139. Rest of Europe Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 140. Rest of Europe Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 141. Rest of Europe Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 142. MEA Intranasal Corticosteroids, by Country USD Million (2014-2019)
  • Table 143. MEA Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 144. MEA Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 145. MEA Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 146. MEA Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 147. MEA Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 148. MEA Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 149. Middle East Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 150. Middle East Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 151. Middle East Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 152. Middle East Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 153. Middle East Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 154. Middle East Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 155. Africa Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 156. Africa Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 157. Africa Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 158. Africa Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 159. Africa Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 160. Africa Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 161. North America Intranasal Corticosteroids, by Country USD Million (2014-2019)
  • Table 162. North America Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 163. North America Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 164. North America Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 165. North America Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 166. North America Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 167. North America Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 168. United States Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 169. United States Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 170. United States Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 171. United States Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 172. United States Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 173. United States Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 174. Canada Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 175. Canada Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 176. Canada Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 177. Canada Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 178. Canada Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 179. Canada Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 180. Mexico Intranasal Corticosteroids, by Type USD Million (2014-2019)
  • Table 181. Mexico Intranasal Corticosteroids, by Application USD Million (2014-2019)
  • Table 182. Mexico Intranasal Corticosteroids, by Indication USD Million (2014-2019)
  • Table 183. Mexico Intranasal Corticosteroids, by Dosage USD Million (2014-2019)
  • Table 184. Mexico Intranasal Corticosteroids, by End User USD Million (2014-2019)
  • Table 185. Mexico Intranasal Corticosteroids, by System USD Million (2014-2019)
  • Table 186. Intranasal Corticosteroids Sales: by Type(K Units)
  • Table 187. Intranasal Corticosteroids Sales Prescribed Drugs , by Region K Units (2014-2019)
  • Table 188. Intranasal Corticosteroids Sales OTC Drugs , by Region K Units (2014-2019)
  • Table 189. Intranasal Corticosteroids Sales: by Application(K Units)
  • Table 190. Intranasal Corticosteroids Sales Hospital Pharmacies , by Region K Units (2014-2019)
  • Table 191. Intranasal Corticosteroids Sales Online Pharnacies , by Region K Units (2014-2019)
  • Table 192. Intranasal Corticosteroids Sales Retail Pharmacies , by Region K Units (2014-2019)
  • Table 193. Intranasal Corticosteroids Sales: by Indication(K Units)
  • Table 194. Intranasal Corticosteroids Sales Perennial Allergic Rhinitis (PAR) , by Region K Units (2014-2019)
  • Table 195. Intranasal Corticosteroids Sales Seasonal Allergic Rhinitis (SAR) , by Region K Units (2014-2019)
  • Table 196. Intranasal Corticosteroids Sales Nonallergic Rhinitis , by Region K Units (2014-2019)
  • Table 197. Intranasal Corticosteroids Sales: by Dosage(K Units)
  • Table 198. Intranasal Corticosteroids Sales Spray , by Region K Units (2014-2019)
  • Table 199. Intranasal Corticosteroids Sales Aerosol Liquid , by Region K Units (2014-2019)
  • Table 200. Intranasal Corticosteroids Sales Implant , by Region K Units (2014-2019)
  • Table 201. Intranasal Corticosteroids Sales: by End User(K Units)
  • Table 202. Intranasal Corticosteroids Sales Hospital Pharmacies , by Region K Units (2014-2019)
  • Table 203. Intranasal Corticosteroids Sales Drug Stores , by Region K Units (2014-2019)
  • Table 204. Intranasal Corticosteroids Sales Retail Pharmacies , by Region K Units (2014-2019)
  • Table 205. Intranasal Corticosteroids Sales Online Pharmacies , by Region K Units (2014-2019)
  • Table 206. Intranasal Corticosteroids Sales: by System(K Units)
  • Table 207. Intranasal Corticosteroids Sales Multi-dose Systems , by Region K Units (2014-2019)
  • Table 208. Intranasal Corticosteroids Sales Bi-dose Systems , by Region K Units (2014-2019)
  • Table 209. Intranasal Corticosteroids Sales Unit-dose Systems , by Region K Units (2014-2019)
  • Table 210. South America Intranasal Corticosteroids Sales, by Country K Units (2014-2019)
  • Table 211. South America Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 212. South America Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 213. South America Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 214. South America Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 215. South America Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 216. South America Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 217. Brazil Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 218. Brazil Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 219. Brazil Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 220. Brazil Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 221. Brazil Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 222. Brazil Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 223. Argentina Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 224. Argentina Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 225. Argentina Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 226. Argentina Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 227. Argentina Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 228. Argentina Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 229. Rest of South America Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 230. Rest of South America Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 231. Rest of South America Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 232. Rest of South America Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 233. Rest of South America Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 234. Rest of South America Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 235. Asia Pacific Intranasal Corticosteroids Sales, by Country K Units (2014-2019)
  • Table 236. Asia Pacific Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 237. Asia Pacific Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 238. Asia Pacific Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 239. Asia Pacific Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 240. Asia Pacific Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 241. Asia Pacific Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 242. China Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 243. China Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 244. China Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 245. China Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 246. China Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 247. China Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 248. Japan Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 249. Japan Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 250. Japan Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 251. Japan Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 252. Japan Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 253. Japan Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 254. India Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 255. India Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 256. India Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 257. India Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 258. India Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 259. India Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 260. South Korea Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 261. South Korea Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 262. South Korea Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 263. South Korea Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 264. South Korea Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 265. South Korea Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 266. Taiwan Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 267. Taiwan Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 268. Taiwan Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 269. Taiwan Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 270. Taiwan Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 271. Taiwan Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 272. Australia Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 273. Australia Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 274. Australia Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 275. Australia Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 276. Australia Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 277. Australia Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 278. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 279. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 280. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 281. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 282. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 283. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 284. Europe Intranasal Corticosteroids Sales, by Country K Units (2014-2019)
  • Table 285. Europe Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 286. Europe Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 287. Europe Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 288. Europe Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 289. Europe Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 290. Europe Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 291. Germany Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 292. Germany Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 293. Germany Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 294. Germany Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 295. Germany Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 296. Germany Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 297. France Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 298. France Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 299. France Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 300. France Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 301. France Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 302. France Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 303. Italy Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 304. Italy Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 305. Italy Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 306. Italy Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 307. Italy Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 308. Italy Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 309. United Kingdom Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 310. United Kingdom Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 311. United Kingdom Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 312. United Kingdom Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 313. United Kingdom Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 314. United Kingdom Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 315. Netherlands Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 316. Netherlands Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 317. Netherlands Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 318. Netherlands Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 319. Netherlands Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 320. Netherlands Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 321. Rest of Europe Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 322. Rest of Europe Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 323. Rest of Europe Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 324. Rest of Europe Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 325. Rest of Europe Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 326. Rest of Europe Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 327. MEA Intranasal Corticosteroids Sales, by Country K Units (2014-2019)
  • Table 328. MEA Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 329. MEA Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 330. MEA Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 331. MEA Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 332. MEA Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 333. MEA Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 334. Middle East Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 335. Middle East Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 336. Middle East Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 337. Middle East Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 338. Middle East Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 339. Middle East Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 340. Africa Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 341. Africa Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 342. Africa Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 343. Africa Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 344. Africa Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 345. Africa Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 346. North America Intranasal Corticosteroids Sales, by Country K Units (2014-2019)
  • Table 347. North America Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 348. North America Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 349. North America Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 350. North America Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 351. North America Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 352. North America Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 353. United States Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 354. United States Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 355. United States Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 356. United States Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 357. United States Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 358. United States Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 359. Canada Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 360. Canada Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 361. Canada Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 362. Canada Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 363. Canada Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 364. Canada Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 365. Mexico Intranasal Corticosteroids Sales, by Type K Units (2014-2019)
  • Table 366. Mexico Intranasal Corticosteroids Sales, by Application K Units (2014-2019)
  • Table 367. Mexico Intranasal Corticosteroids Sales, by Indication K Units (2014-2019)
  • Table 368. Mexico Intranasal Corticosteroids Sales, by Dosage K Units (2014-2019)
  • Table 369. Mexico Intranasal Corticosteroids Sales, by End User K Units (2014-2019)
  • Table 370. Mexico Intranasal Corticosteroids Sales, by System K Units (2014-2019)
  • Table 371. Company Basic Information, Sales Area and Its Competitors
  • Table 372. Company Basic Information, Sales Area and Its Competitors
  • Table 373. Company Basic Information, Sales Area and Its Competitors
  • Table 374. Company Basic Information, Sales Area and Its Competitors
  • Table 375. Company Basic Information, Sales Area and Its Competitors
  • Table 376. Company Basic Information, Sales Area and Its Competitors
  • Table 377. Company Basic Information, Sales Area and Its Competitors
  • Table 378. Company Basic Information, Sales Area and Its Competitors
  • Table 379. Company Basic Information, Sales Area and Its Competitors
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Intranasal Corticosteroids: by Type(USD Million)
  • Table 382. Intranasal Corticosteroids Prescribed Drugs , by Region USD Million (2020-2025)
  • Table 383. Intranasal Corticosteroids OTC Drugs , by Region USD Million (2020-2025)
  • Table 384. Intranasal Corticosteroids: by Application(USD Million)
  • Table 385. Intranasal Corticosteroids Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 386. Intranasal Corticosteroids Online Pharnacies , by Region USD Million (2020-2025)
  • Table 387. Intranasal Corticosteroids Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 388. Intranasal Corticosteroids: by Indication(USD Million)
  • Table 389. Intranasal Corticosteroids Perennial Allergic Rhinitis (PAR) , by Region USD Million (2020-2025)
  • Table 390. Intranasal Corticosteroids Seasonal Allergic Rhinitis (SAR) , by Region USD Million (2020-2025)
  • Table 391. Intranasal Corticosteroids Nonallergic Rhinitis , by Region USD Million (2020-2025)
  • Table 392. Intranasal Corticosteroids: by Dosage(USD Million)
  • Table 393. Intranasal Corticosteroids Spray , by Region USD Million (2020-2025)
  • Table 394. Intranasal Corticosteroids Aerosol Liquid , by Region USD Million (2020-2025)
  • Table 395. Intranasal Corticosteroids Implant , by Region USD Million (2020-2025)
  • Table 396. Intranasal Corticosteroids: by End User(USD Million)
  • Table 397. Intranasal Corticosteroids Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 398. Intranasal Corticosteroids Drug Stores , by Region USD Million (2020-2025)
  • Table 399. Intranasal Corticosteroids Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 400. Intranasal Corticosteroids Online Pharmacies , by Region USD Million (2020-2025)
  • Table 401. Intranasal Corticosteroids: by System(USD Million)
  • Table 402. Intranasal Corticosteroids Multi-dose Systems , by Region USD Million (2020-2025)
  • Table 403. Intranasal Corticosteroids Bi-dose Systems , by Region USD Million (2020-2025)
  • Table 404. Intranasal Corticosteroids Unit-dose Systems , by Region USD Million (2020-2025)
  • Table 405. South America Intranasal Corticosteroids, by Country USD Million (2020-2025)
  • Table 406. South America Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 407. South America Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 408. South America Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 409. South America Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 410. South America Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 411. South America Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 412. Brazil Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 413. Brazil Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 414. Brazil Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 415. Brazil Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 416. Brazil Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 417. Brazil Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 418. Argentina Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 419. Argentina Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 420. Argentina Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 421. Argentina Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 422. Argentina Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 423. Argentina Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 424. Rest of South America Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 425. Rest of South America Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 426. Rest of South America Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 427. Rest of South America Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 428. Rest of South America Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 429. Rest of South America Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 430. Asia Pacific Intranasal Corticosteroids, by Country USD Million (2020-2025)
  • Table 431. Asia Pacific Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 432. Asia Pacific Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 433. Asia Pacific Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 434. Asia Pacific Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 435. Asia Pacific Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 436. Asia Pacific Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 437. China Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 438. China Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 439. China Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 440. China Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 441. China Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 442. China Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 443. Japan Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 444. Japan Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 445. Japan Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 446. Japan Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 447. Japan Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 448. Japan Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 449. India Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 450. India Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 451. India Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 452. India Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 453. India Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 454. India Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 455. South Korea Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 456. South Korea Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 457. South Korea Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 458. South Korea Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 459. South Korea Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 460. South Korea Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 461. Taiwan Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 462. Taiwan Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 463. Taiwan Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 464. Taiwan Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 465. Taiwan Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 466. Taiwan Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 467. Australia Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 468. Australia Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 469. Australia Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 470. Australia Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 471. Australia Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 472. Australia Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 473. Rest of Asia-Pacific Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 474. Rest of Asia-Pacific Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 475. Rest of Asia-Pacific Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 476. Rest of Asia-Pacific Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 477. Rest of Asia-Pacific Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 478. Rest of Asia-Pacific Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 479. Europe Intranasal Corticosteroids, by Country USD Million (2020-2025)
  • Table 480. Europe Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 481. Europe Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 482. Europe Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 483. Europe Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 484. Europe Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 485. Europe Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 486. Germany Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 487. Germany Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 488. Germany Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 489. Germany Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 490. Germany Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 491. Germany Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 492. France Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 493. France Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 494. France Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 495. France Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 496. France Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 497. France Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 498. Italy Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 499. Italy Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 500. Italy Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 501. Italy Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 502. Italy Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 503. Italy Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 504. United Kingdom Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 505. United Kingdom Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 506. United Kingdom Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 507. United Kingdom Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 508. United Kingdom Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 509. United Kingdom Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 510. Netherlands Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 511. Netherlands Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 512. Netherlands Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 513. Netherlands Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 514. Netherlands Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 515. Netherlands Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 516. Rest of Europe Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 517. Rest of Europe Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 518. Rest of Europe Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 519. Rest of Europe Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 520. Rest of Europe Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 521. Rest of Europe Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 522. MEA Intranasal Corticosteroids, by Country USD Million (2020-2025)
  • Table 523. MEA Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 524. MEA Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 525. MEA Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 526. MEA Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 527. MEA Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 528. MEA Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 529. Middle East Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 530. Middle East Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 531. Middle East Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 532. Middle East Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 533. Middle East Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 534. Middle East Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 535. Africa Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 536. Africa Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 537. Africa Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 538. Africa Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 539. Africa Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 540. Africa Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 541. North America Intranasal Corticosteroids, by Country USD Million (2020-2025)
  • Table 542. North America Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 543. North America Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 544. North America Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 545. North America Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 546. North America Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 547. North America Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 548. United States Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 549. United States Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 550. United States Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 551. United States Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 552. United States Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 553. United States Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 554. Canada Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 555. Canada Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 556. Canada Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 557. Canada Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 558. Canada Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 559. Canada Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 560. Mexico Intranasal Corticosteroids, by Type USD Million (2020-2025)
  • Table 561. Mexico Intranasal Corticosteroids, by Application USD Million (2020-2025)
  • Table 562. Mexico Intranasal Corticosteroids, by Indication USD Million (2020-2025)
  • Table 563. Mexico Intranasal Corticosteroids, by Dosage USD Million (2020-2025)
  • Table 564. Mexico Intranasal Corticosteroids, by End User USD Million (2020-2025)
  • Table 565. Mexico Intranasal Corticosteroids, by System USD Million (2020-2025)
  • Table 566. Intranasal Corticosteroids Sales: by Type(K Units)
  • Table 567. Intranasal Corticosteroids Sales Prescribed Drugs , by Region K Units (2020-2025)
  • Table 568. Intranasal Corticosteroids Sales OTC Drugs , by Region K Units (2020-2025)
  • Table 569. Intranasal Corticosteroids Sales: by Application(K Units)
  • Table 570. Intranasal Corticosteroids Sales Hospital Pharmacies , by Region K Units (2020-2025)
  • Table 571. Intranasal Corticosteroids Sales Online Pharnacies , by Region K Units (2020-2025)
  • Table 572. Intranasal Corticosteroids Sales Retail Pharmacies , by Region K Units (2020-2025)
  • Table 573. Intranasal Corticosteroids Sales: by Indication(K Units)
  • Table 574. Intranasal Corticosteroids Sales Perennial Allergic Rhinitis (PAR) , by Region K Units (2020-2025)
  • Table 575. Intranasal Corticosteroids Sales Seasonal Allergic Rhinitis (SAR) , by Region K Units (2020-2025)
  • Table 576. Intranasal Corticosteroids Sales Nonallergic Rhinitis , by Region K Units (2020-2025)
  • Table 577. Intranasal Corticosteroids Sales: by Dosage(K Units)
  • Table 578. Intranasal Corticosteroids Sales Spray , by Region K Units (2020-2025)
  • Table 579. Intranasal Corticosteroids Sales Aerosol Liquid , by Region K Units (2020-2025)
  • Table 580. Intranasal Corticosteroids Sales Implant , by Region K Units (2020-2025)
  • Table 581. Intranasal Corticosteroids Sales: by End User(K Units)
  • Table 582. Intranasal Corticosteroids Sales Hospital Pharmacies , by Region K Units (2020-2025)
  • Table 583. Intranasal Corticosteroids Sales Drug Stores , by Region K Units (2020-2025)
  • Table 584. Intranasal Corticosteroids Sales Retail Pharmacies , by Region K Units (2020-2025)
  • Table 585. Intranasal Corticosteroids Sales Online Pharmacies , by Region K Units (2020-2025)
  • Table 586. Intranasal Corticosteroids Sales: by System(K Units)
  • Table 587. Intranasal Corticosteroids Sales Multi-dose Systems , by Region K Units (2020-2025)
  • Table 588. Intranasal Corticosteroids Sales Bi-dose Systems , by Region K Units (2020-2025)
  • Table 589. Intranasal Corticosteroids Sales Unit-dose Systems , by Region K Units (2020-2025)
  • Table 590. South America Intranasal Corticosteroids Sales, by Country K Units (2020-2025)
  • Table 591. South America Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 592. South America Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 593. South America Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 594. South America Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 595. South America Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 596. South America Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 597. Brazil Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 598. Brazil Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 599. Brazil Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 600. Brazil Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 601. Brazil Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 602. Brazil Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 603. Argentina Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 604. Argentina Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 605. Argentina Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 606. Argentina Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 607. Argentina Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 608. Argentina Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 609. Rest of South America Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 610. Rest of South America Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 611. Rest of South America Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 612. Rest of South America Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 613. Rest of South America Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 614. Rest of South America Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 615. Asia Pacific Intranasal Corticosteroids Sales, by Country K Units (2020-2025)
  • Table 616. Asia Pacific Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 617. Asia Pacific Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 618. Asia Pacific Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 619. Asia Pacific Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 620. Asia Pacific Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 621. Asia Pacific Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 622. China Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 623. China Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 624. China Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 625. China Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 626. China Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 627. China Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 628. Japan Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 629. Japan Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 630. Japan Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 631. Japan Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 632. Japan Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 633. Japan Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 634. India Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 635. India Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 636. India Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 637. India Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 638. India Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 639. India Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 640. South Korea Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 641. South Korea Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 642. South Korea Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 643. South Korea Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 644. South Korea Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 645. South Korea Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 646. Taiwan Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 647. Taiwan Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 648. Taiwan Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 649. Taiwan Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 650. Taiwan Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 651. Taiwan Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 652. Australia Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 653. Australia Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 654. Australia Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 655. Australia Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 656. Australia Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 657. Australia Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 658. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 659. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 660. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 661. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 662. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 663. Rest of Asia-Pacific Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 664. Europe Intranasal Corticosteroids Sales, by Country K Units (2020-2025)
  • Table 665. Europe Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 666. Europe Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 667. Europe Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 668. Europe Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 669. Europe Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 670. Europe Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 671. Germany Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 672. Germany Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 673. Germany Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 674. Germany Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 675. Germany Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 676. Germany Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 677. France Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 678. France Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 679. France Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 680. France Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 681. France Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 682. France Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 683. Italy Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 684. Italy Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 685. Italy Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 686. Italy Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 687. Italy Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 688. Italy Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 689. United Kingdom Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 690. United Kingdom Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 691. United Kingdom Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 692. United Kingdom Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 693. United Kingdom Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 694. United Kingdom Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 695. Netherlands Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
  • Table 696. Netherlands Intranasal Corticosteroids Sales, by Application K Units (2020-2025)
  • Table 697. Netherlands Intranasal Corticosteroids Sales, by Indication K Units (2020-2025)
  • Table 698. Netherlands Intranasal Corticosteroids Sales, by Dosage K Units (2020-2025)
  • Table 699. Netherlands Intranasal Corticosteroids Sales, by End User K Units (2020-2025)
  • Table 700. Netherlands Intranasal Corticosteroids Sales, by System K Units (2020-2025)
  • Table 701. Rest of Europe Intranasal Corticosteroids Sales, by Type K Units (2020-2025)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Intranasal Corticosteroids: by Type USD Million (2014-2019)
  • Figure 5. Global Intranasal Corticosteroids: by Application USD Million (2014-2019)
  • Figure 6. Global Intranasal Corticosteroids: by Indication USD Million (2014-2019)
  • Figure 7. Global Intranasal Corticosteroids: by Dosage USD Million (2014-2019)
  • Figure 8. Global Intranasal Corticosteroids: by End User USD Million (2014-2019)
  • Figure 9. Global Intranasal Corticosteroids: by System USD Million (2014-2019)
  • Figure 10. South America Intranasal Corticosteroids Share (%), by Country
  • Figure 11. Asia Pacific Intranasal Corticosteroids Share (%), by Country
  • Figure 12. Europe Intranasal Corticosteroids Share (%), by Country
  • Figure 13. MEA Intranasal Corticosteroids Share (%), by Country
  • Figure 14. North America Intranasal Corticosteroids Share (%), by Country
  • Figure 15. Global Intranasal Corticosteroids: by Type K Units (2014-2019)
  • Figure 16. Global Intranasal Corticosteroids: by Application K Units (2014-2019)
  • Figure 17. Global Intranasal Corticosteroids: by Indication K Units (2014-2019)
  • Figure 18. Global Intranasal Corticosteroids: by Dosage K Units (2014-2019)
  • Figure 19. Global Intranasal Corticosteroids: by End User K Units (2014-2019)
  • Figure 20. Global Intranasal Corticosteroids: by System K Units (2014-2019)
  • Figure 21. South America Intranasal Corticosteroids Share (%), by Country
  • Figure 22. Asia Pacific Intranasal Corticosteroids Share (%), by Country
  • Figure 23. Europe Intranasal Corticosteroids Share (%), by Country
  • Figure 24. MEA Intranasal Corticosteroids Share (%), by Country
  • Figure 25. North America Intranasal Corticosteroids Share (%), by Country
  • Figure 26. Global Intranasal Corticosteroids share by Players 2019 (%)
  • Figure 27. Global Intranasal Corticosteroids share by Players (Top 3) 2019(%)
  • Figure 28. Global Intranasal Corticosteroids share by Players (Top 5) 2019(%)
  • Figure 29. BCG Matrix for key Companies
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2019
  • Figure 32. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck (United States) Revenue: by Geography 2019
  • Figure 34. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi (France) Revenue: by Geography 2019
  • Figure 36. Sumitomo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Sumitomo Corporation (Japan) Revenue: by Geography 2019
  • Figure 38. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 39. Teva Pharmaceuticals (Israel) Revenue: by Geography 2019
  • Figure 40. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 41. Johnson and Johnson (United States) Revenue: by Geography 2019
  • Figure 42. AstraZeneca(United Kingdom) Revenue, Net Income and Gross profit
  • Figure 43. AstraZeneca(United Kingdom) Revenue: by Geography 2019
  • Figure 44. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 46. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 47. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 48. Pfizer, Inc. (United States Revenue, Net Income and Gross profit
  • Figure 49. Pfizer, Inc. (United States Revenue: by Geography 2019
  • Figure 50. Global Intranasal Corticosteroids: by Type USD Million (2020-2025)
  • Figure 51. Global Intranasal Corticosteroids: by Application USD Million (2020-2025)
  • Figure 52. Global Intranasal Corticosteroids: by Indication USD Million (2020-2025)
  • Figure 53. Global Intranasal Corticosteroids: by Dosage USD Million (2020-2025)
  • Figure 54. Global Intranasal Corticosteroids: by End User USD Million (2020-2025)
  • Figure 55. Global Intranasal Corticosteroids: by System USD Million (2020-2025)
  • Figure 56. South America Intranasal Corticosteroids Share (%), by Country
  • Figure 57. Asia Pacific Intranasal Corticosteroids Share (%), by Country
  • Figure 58. Europe Intranasal Corticosteroids Share (%), by Country
  • Figure 59. MEA Intranasal Corticosteroids Share (%), by Country
  • Figure 60. North America Intranasal Corticosteroids Share (%), by Country
  • Figure 61. Global Intranasal Corticosteroids: by Type K Units (2020-2025)
  • Figure 62. Global Intranasal Corticosteroids: by Application K Units (2020-2025)
  • Figure 63. Global Intranasal Corticosteroids: by Indication K Units (2020-2025)
  • Figure 64. Global Intranasal Corticosteroids: by Dosage K Units (2020-2025)
  • Figure 65. Global Intranasal Corticosteroids: by End User K Units (2020-2025)
  • Figure 66. Global Intranasal Corticosteroids: by System K Units (2020-2025)
  • Figure 67. South America Intranasal Corticosteroids Share (%), by Country
  • Figure 68. Asia Pacific Intranasal Corticosteroids Share (%), by Country
  • Figure 69. Europe Intranasal Corticosteroids Share (%), by Country
  • Figure 70. MEA Intranasal Corticosteroids Share (%), by Country
  • Figure 71. North America Intranasal Corticosteroids Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline (United Kingdom)
  • Merck (United States)
  • Sanofi (France)
  • Sumitomo Corporation (Japan)
  • Teva Pharmaceuticals (Israel)
  • Johnson and Johnson (United States)
  • AstraZeneca(United Kingdom)
  • Merck & Co., Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States
Additional players considered in the study are as follows:
Pfizer, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation